Search - tctmd.com

Displaying 1 - 9 of 9

Sort: Relevancy | Date

REDWOOD-HCM OLE: Aficamten Improves Patient-Measured Health Status

News Conference News HFSA 2022

REDWOOD-HCM OLE: Aficamten Improves Patient-Measured Health Status

October 07, 2022

Both Surgical, Percutaneous Closure Boost Survival in Post-STEMI VSD

News Conference News TCT 2022

Both Surgical, Percutaneous Closure Boost Survival in Post-STEMI VSD

September 18, 2022

HF Devices Have a Role to Play, Even With Today’s GDMT Bonanza

News Conference News TCT 2022

HF Devices Have a Role to Play, Even With Today’s GDMT Bonanza

September 16, 2022

New Faces, New Formats, New Tech: What to Expect From TCT 2022

News Conference News TCT 2022

New Faces, New Formats, New Tech: What to Expect From TCT 2022

September 07, 2022

Aficamten Safe, Effective for Up to 6 months in Obstructive HCM: REDWOOD-HCM OLE

News Conference News ESC Heart Failure 2022

Aficamten Safe, Effective for Up to 6 Months in Obstructive HCM: REDWOOD-HCM OLE

May 31, 2022

Mavacamten Yields Stable Benefits in Obstructive HCM Over Longer Term

News Conference News ACC 2022

Mavacamten Yields Stable Benefits in Obstructive HCM Over Longer Term

April 03, 2022

Mavacamten Slashes Need for Septal Reduction in Obstructive HCM: VALOR-HCM

News Conference News ACC 2022

Mavacamten Slashes Need for Septal Reduction in Obstructive HCM: VALOR-HCM

Yael L. Maxwell

April 02, 2022

What’s Going to Be Hot at ACC 2022, In Person or Virtual

News Conference News ACC 2022

What’s Going to Be Hot at ACC 2022, In Person or Virtual

March 28, 2022

LAVA ECMO: Early Data Point to Hemodynamic Benefits, Safety

News Conference News THT 2022

LAVA ECMO: Early Data Point to Hemodynamic Benefits, Safety

February 02, 2022

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.